1. Subclinical myocardial damage after anthracycline chemotherapy in Japanese patients with breast cancer.
- Author
-
Nakatsuma, Kenji, Ozasa, Neiko, Ohno, Mikiko, Ishiguro, Hiroshi, Minami, Manabu, Nishi, Eiichiro, Toi, Masakazu, Ono, Koh, and Kimura, Takeshi
- Abstract
Data on the incidence, timing, and severity of myocardial damage after anthracycline-based chemotherapy (AC) in Japanese patients with breast cancer are limited. We evaluated cancer therapy-related cardiac dysfunction (CTRCD) in Japanese women with breast cancer (n = 51) after the first AC according to the definitions of the 2022 European Society of Cardiology onco-cardiology guideline, including assessment of high-sensitivity troponin I (TnI) and B-type natriuretic peptide (BNP) levels. CTRCD was detected in 67 % of the patients (3.9 %, 7.8 %, 9.8 %, 43 %, 37 %, 22 %, 20 %, and 9.8 % of patients at 1 week and 1, 2, 3, 6, 9, 12, and 15 months post-AC, respectively) without significant left ventricular ejection fraction reduction (<50 %) and heart failure. Elevated TnI levels (>26 pg/mL) were found in 43 % of patients, and elevated BNP levels (≥35 pg/mL) were observed in 22 % of patients during the follow-up period. Approximately two-thirds of the Japanese patients in this study experienced CTRCD, which was frequently observed at 3 or 6 months post-AC. However, all patients with CTRCD were diagnosed with mild asymptomatic CTRCD. Although, these patients were diagnosed with mild asymptomatic CTRCD, careful long-term follow-up will be required. [Display omitted] • Two-thirds of the Japanese patients experienced cancer therapy-related cardiac dysfunction (CTRCD). • CTRCD was frequently observed at 3 or 6 months post-anthracycline-based chemotherapy. • All patients with CTRCD were diagnosed with mild asymptomatic CTRCD. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF